Chem.jpg (Chem)
Alendronate Sodium Solution
Product Images NDC 0054-0282
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 0054-0282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig3-multi.jpg (Fig3 Multi)
This is a chart showing the mean percentage change from baseline for a multinational study comparing Alendronate 10 mg versus a placebo over a period of 36 months (3 years). The chart shows results at time points of 0, 12, 24, and 36 months.*
Fig3-us.jpg (Fig3 Us)
The text represents a figure or a chart showing the mean percentage change from baseline with standard error in a U.S. study comparing the efficacy of 10 mg Alendronate compared to the Placebo over a period of 36 months. It is not possible to accurately evaluate the data without the accompanying figure.*
Figure1.jpg (Figure1)
This text represents a table showing the cumulative incidence in percentage for both Placebo and Alendronate, over a period of time represented in months. There is no other information available.*
Figure2.jpg (Figure2)
Figure4.jpg (Figure4)
This text is a chart displaying the results of a study on the effect of Alendronate 5mg per day on bone mineral density (BMD) in postmenopausal women with osteoporosis. The chart shows the change in BMD from baseline after a 2-year and a 3-year study period compared to a placebo. The BMD percentage changes are shown separately for the lumbar spine, femoral neck, trochanter, and total body.*
Figure5.jpg (Figure5)
Figure6.jpg (Figure6)
The text describes the effect of Alendronate and Etidronate drugs on serum alkaline phosphatase in studies conducted in Paget's Disease of Bone. The text presents the mean % change from baseline for serum alkaline phosphate levels for the drugs and a placebo, 20, -20, -60, and -100, respectively. The studies included a multinational study of Alendronate 40mg/day and a US study of Alendronate 40mg/day. The time frame for the studies was 0, 3, and 6 months.*
0054-0282-59 (Image 01)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
